Soleno Therapeutics Faces Class Action Lawsuit Over Drug Safety Concerns

ClaimsFiler Reminds Investors With Losses Over $100,000 to File Lead Plaintiff Application by May 5, 2026

Mar. 12, 2026 at 1:36am

Got story updates? Submit your updates here. ›

A class action lawsuit has been filed against Soleno Therapeutics, Inc. alleging the company failed to disclose material information about safety concerns with its only commercial product, DCCR, during the treatment of hyperphagia in individuals with Prader-Willi syndrome. The lawsuit claims Soleno systematically minimized, mischaracterized, and failed to disclose evidence of potential safety issues, including indications of excessive fluid retention among clinical trial participants. As a result, the lawsuit alleges DCCR posed materially greater safety risks than disclosed, lowering its commercial viability.

Why it matters

This case highlights the importance of pharmaceutical companies fully disclosing safety data and potential risks associated with their drug candidates, especially for treatments targeting rare and serious medical conditions like Prader-Willi syndrome. Failure to do so can lead to legal action by investors who suffer losses due to undisclosed information that impacts a drug's commercial prospects.

The details

The class action lawsuit alleges that Soleno and certain executives failed to disclose that the Phase 3 clinical trial program for DCCR, its only commercial product, systematically minimized, mischaracterized, and/or failed to disclose substantial evidence of potential safety concerns associated with its administration, including indications of excessive fluid retention among clinical trial participants. As a result, the lawsuit claims DCCR posed materially greater safety risks than disclosed, lowering its commercial viability due to factors like higher patient discontinuation rates, lower adoption, prescriber reluctance, regulatory action, and potential reputational and legal fallout.

  • The class period covers March 26, 2025 to November 4, 2025.
  • The lead plaintiff application deadline is May 5, 2026.

The players

Soleno Therapeutics, Inc.

A biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

ClaimsFiler

A free shareholder information service that reminds investors of lead plaintiff deadlines in class action lawsuits.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on May 5, 2026 whether to allow the case to proceed as a class action lawsuit.

The takeaway

This case underscores the need for pharmaceutical companies to be fully transparent about safety data and potential risks associated with their drug candidates, especially for treatments targeting rare and serious medical conditions. Failure to disclose material information can lead to legal action by investors who suffer losses due to undisclosed information that impacts a drug's commercial prospects.